Ovid Therapeutics/$OVID

1D1W1MYTD1Y5YMAX

About Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ticker
$OVID
Sector
Health
Primary listing
NASDAQ
Employees
23
Headquarters
New York, United States
Website
www.ovidrx.com

OVID Metrics

BasicAdvanced
$475M
-
-$0.28
0.25
-

What the Analysts think about OVID

Analyst ratings (Buy, Hold, Sell) for Ovid Therapeutics stock.
Analyst projections of the future price of Ovid Therapeutics stock.

Bulls say / Bears say

OV329’s early clinical package is encouraging: 7 mg and 9 mg cohorts showed favourable safety and tolerability with no treatment-related serious adverse events, while pharmacokinetics reached targeted exposure levels. That supports progression into a placebo-controlled Phase 2 focal-seizure efficacy trial. (Ovid Therapeutics)
The programme could address more than focal seizures, with Ovid planning proof-of-concept studies in TSC-associated seizures and infantile spasms, while its KCC2 direct-activator library offers additional neurological optionality. (Ovid Therapeutics, Ovid Therapeutics)
Funding risk has eased: cash and marketable securities were $165.6 million at 31 March, followed by $27.3 million of warrant proceeds and a $60 million private placement. Ovid says these proceeds extend its runway into 2029, giving it time to generate several clinical read-outs. (Ovid Therapeutics)
The central investment case still depends on efficacy that has not yet been demonstrated: recent OV329 data were safety, pharmacokinetic and biomarker findings, while the focal-seizure Phase 2 trial was only planned. A clean safety profile does not guarantee meaningful seizure reduction. (Ovid Therapeutics)
The pipeline remains early and concentrated. OV329 is the main clinical programme, while OV4071 and the other KCC2 activators are described as a library in development, leaving substantial preclinical, clinical and regulatory execution risk. (Ovid Therapeutics, Ovid Therapeutics)
Ovid is advancing OV329 while competitors are moving closer to market in focal seizures: Xenon has submitted an NDA for azetukalner after positive Phase 3 data, and Rapport has begun Phase 3 development of RAP-219. These programmes could raise the efficacy and convenience bar before Ovid reaches pivotal studies. (Xenon Pharmaceuticals, Rapport Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

OVID Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

OVID Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing OVID

AllEURGBP
Funds
Fund name
Fund size
$OVID weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.